U.S. Markets open in 2 hrs 57 mins

Oasmia Pharmaceutical AB (publ) (OASM)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.9815-0.0685 (-6.5238%)
At close: 3:57PM EDT
People also watch
SBBPMIRNKTOVBNTCDMTX
Full screen
Previous Close1.0500
Open0.9900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9815 - 0.9900
52 Week Range0.8520 - 3.7000
Volume1,000
Avg. Volume12,534
Market Cap54.53M
BetaN/A
PE Ratio (TTM)-1.88
EPS (TTM)-0.52
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
    Capital Cube3 days ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • GlobeNewswirelast month

    Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

    Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval of Doxophos in Russia, a key milestone following ...

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017
    Capital Cube2 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended April 30, 2017. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -4.71 million. Gross margins narrowed from -51,783.05% to -85,334.09% compared to the same period last year, operating (EBITDA) margins now -82,834.09% from -49,876.27%. Change in operating ... Read more (Read more...)